Integration with Genomics
Imaging complements genomic profiling by providing spatial and functional context to molecular alterations. Radiogenomic approaches correlate imaging phenotypes with genetic signatures to predict behavior and therapy response. Multidisciplinary molecular tumor boards integrate imaging and genomic data for personalized plans.
Molecular Imaging
PET tracers targeting specific receptors or metabolic pathways enable non invasive assessment of target expression and heterogeneity. Theranostic imaging guides selection for targeted radionuclide therapies and monitors biodistribution. Quantitative PET metrics support patient selection and dosimetry planning.
Biomarker Development
Develop imaging biomarkers with rigorous analytical validation and clinical qualification for intended use. Harmonize acquisition and analysis across sites to enable multicenter trials and regulatory acceptance. Combine imaging with liquid biopsies and clinical data to improve predictive models.
Clinical Implementation
Embed imaging biomarkers into clinical workflows with clear reporting templates and decision thresholds. Educate clinicians on interpretation and limitations and track outcomes to refine utility. Collaborate with translational researchers to accelerate biomarker validation and adoption.